1. HBW Insight
  2. >>Health
  4. >>Regulation

Drivers For Allowing OTC Naloxone In US Include Social Justice As Well As Public Health Need

 
• By Hannah Daniel

Communities where opioid overdoses are highest “are less likely to have a physician who can order naloxone for them,” says researcher Nabarun Dasgupta. Naloxone switch developer Michael Hufford says “disconnects” with FDA “continue to hamper and delay OTC naloxone product applications.”

• Source: Alamy

Expanding naloxone access not only is a public health need, but also a social justice issue, according to experts speaking at a Reagan-Udall Foundation webinar on naloxone access in the US.

“The greatest increases in overdose deaths rates are happening in communities of color. Yet harm reduction programs serving those communities...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?

NDA User Fees Increasing 8.6% As FDA Projects More Applications But Fewer Sponsor Meetings

 
• By Nielsen Hobbs and Derrick Gingery

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.

Self-Testing Kits Need To Be Regulated Like OTCs, UK Researchers Argue

 
• By David Ridley

Concerns raised by two recent studies prompt UK researchers to argue for greater regulation with regards to direct-to-consumer test kits.

More from Policy & Regulation